Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Telephone Conversation, June 1, 2012 - MenHibrix


Submission Type: BLA    Submission ID: 125363/0    Office: OVRR
Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine
GlaxoSmithKline Biologicals
Telecon Date/Time: 01-Jun-2012 02:40 AM        Initiated by FDA? Yes
Telephone Number:
Communication Categorie(s):
1. Advice
Telecon Summary:
FDA decision on temp storage for diluent
FDA Participants: None
Non-FDA Participants: None
Trans-BLA Group: No
Related STNs: None
Related PMCs: None
Telecon Body:
After internal discussion, FDA conveyed to GSK that their “batching” of storage data is acceptable. The storage condition for the PI and labels/carton will read;
 "Store refrigerated or at controlled room temperature between 2° and 25°C (36° and 77°F). Do not freeze. Discard if the diluent has been frozen"

Page Last Updated: 09/25/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English